Recent studies provided evidence that SGLT2-i use could be effective also on Non- Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) in patients with T2DM by reducing liver fat accumulation [33,34]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.